ProPhase Labs, Inc. Finance Lease, Right-of-Use Asset, Accumulated Amortization
ProPhase Labs, Inc. (PRPH) had Finance Lease, Right-of-Use Asset, Accumulated Amortization of $3.70 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Leases › Assets and Liabilities, Lessee
us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization · last filed 2026-08-19
- 2026-06-30: Finance Lease, Right-of-Use Asset, Accumulated Amortization $3.70M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $3.40M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $3.10M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, Accumulated Amortization $2.80M.
| Period end | Finance Lease, Right-of-Use Asset, Accumulated Amortization | Finance Lease, Right-of-Use Asset, Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $3.70M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $3.40M 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $3.10M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $2.80M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $3.10M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $2.70M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $2.30M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $2.70M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.70M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.20M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $800.00K 10-K · filed 2025-04-01 | $760.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |